


# Haemochromatosis UK

Trustees' Annual Report and Accounts  
for the year ending 31 December 2018

Haemochromatosis • UK  
Helping people live with iron overload

+Fe



Haemochromatosis UK  
Trustees' Annual Report and Accounts  
For the year ending 31 December 2018

Published April 2019  
© Haemochromatosis UK

[www.haemochromatosis.org.uk](http://www.haemochromatosis.org.uk)

**Contents**

1. Statutory Information	1
2. Introduction from the Chair	2
3. A message from the Chief Executive	2
4. Trustees' Report	3
5. Governance	10
6. Finance	11

**1. Statutory Information**

*Name*

Haemochromatosis UK and HUK are working names of The Haemochromatosis Society

*Regulators*

Charity Commission for England and Wales  
(Charity No. 1001307)  
The Office of the Scottish Charity Regulator  
(Charity No. SCO41701)  
Companies House  
(Company Limited by Guarantee No. 2541361)

*Registered address*

PO Box 6356  
Rugby  
CV21 9PA  
03030 401101  
[office@huk.org.uk](mailto:office@huk.org.uk)

*Independent Financial Examiner*

Hicks and Company Chartered Accountants  
30 Market Place  
Hitchin  
SG5 1DY  
01462 437117  
[geoffrey.hodge@hicks.co.uk](mailto:geoffrey.hodge@hicks.co.uk)

*Bankers*

CAF Bank Ltd, West Malling (principal)  
Shawbrook Bank, Brentwood, London  
The Royal Bank of Scotland, Rugby, Warwickshire

*Trustees at 31 Dec 2018*

<u>Name</u>	<u>2018 Meetings</u>
Dr Roseanna Brady	5 of 6
Ms Lisa Flude	6 of 6
Miss Katharine Hough	3 of 3 *
Mr Roger Keyte (Treasurer)	6 of 6
Mr Neil McClements	6 of 6
Dr Stuart McDonald	4 of 6
Ms Corrina Towers (Chair)	6 of 6
Mrs Michelle Weerasekera	2 of 2 **

\* appointed July

\*\* appointed October

*Trustees resigning in 2018*

Mr Howard Don MBA  
Mr Paul Hirons  
Mr Nick Howes  
Dr Caty Worlock Pope



## 2. Introduction from the Chair

2018 has been a significant year for us at HUK in many ways. We exceeded not only our financial targets, but also our aspirational ones. Alongside delivering core services such as our trusted Patient Information Days, our helpline and our annual conference, we started to truly advocate for change when we launched the findings of our 2017 large-scale patient survey at the House of Commons. This led directly to a number of exciting initiatives, which could see significant improvements in the quality and consistency of treatment and care of GH patients across the UK.

Our executive team grew with the development of a communications function, and we secured corporate and grant-based funding to new levels to help build our sustainability. The trustee and executive teams worked closely together to take a formative idea (developed by former trustee David Widden) to the reality of a three year Genetic Haemochromatosis Education Programme, for which we are recruiting a full time Manager.



We remain grateful to members who support us, the people who personally fundraise and volunteer for us, and the companies and trusts that commit to fund us. Without their generosity of spirit and time, financial support and commitment to our cause, we would simply be unable to do what we do. Also, on behalf of trustees, I would like to thank our Chief Executive David Head and his team for their hard work during 2018.

I am excited for the next year as we continue to raise awareness, educate healthcare professionals, support patients and families, and encourage research to help people live with iron overload.

A handwritten signature in blue ink that reads "Corrina Towers".

Corrina Towers  
Chair

## 3. A message from the Chief Executive

In my four years with the charity, it seems to me that 2018 was a pivotal time for the organisation. We have spent much of those four years working to open the "can of worms" that is genetic haemochromatosis. We have known for a long time that our NHS needs to pay more attention and in 2018 we really succeeded in shifting our cause up the national agenda. To continue the analogy, the can is well and truly open.



Our large patient survey in 2017, the resulting report commissioned in 2018, a major event at The House of Commons, and the creation of an All Party Parliamentary Group for Genetic Haemochromatosis have given us influence at high levels. 2018 also saw acknowledgment from the National Institute for Health and Care Excellence (NICE) that GH needs to be managed properly in the UK. I believe that we must now invest resources – time, money and expertise – in exercising our influence effectively. I am delighted that the board are preparing to do this as we head into 2019.

All of this is built on an important foundation – our membership and our roots as a patient led, patient driven, patient focused organisation. Haemochromatosis UK relies on an amazing mutually beneficial relationship with our membership without which we could never have achieved as much as we have achieved in 2018.

When we look back in the future, I am sure this will prove to be one of the most important times in our history. It truly is an exciting time for us at Haemochromatosis UK and I am proud to be a continuing part of it.

A handwritten signature in blue ink that reads "David Head MBA".

David Head MBA  
Chief Executive

## 4. Trustees' Report for 2018

### Background

Genetic haemochromatosis (GH) is a condition that leads to a build-up of iron in the body to toxic levels. In turn this causes a wide range of symptoms and follow on conditions, some of which can be very serious or indeed, in the worst cases, fatal.

Haemochromatosis UK (more formally referred to as The Haemochromatosis Society) exists to do four important things:

- provide information and support to patients and their families;
- educate healthcare professionals, patients and others about GH and its impact;
- raise public awareness of GH and of the importance of early intervention;
- stimulate and influence research into the science, impact and statistics of GH.

In this document, we report progress with these objectives over 2018 and outline plans and aspirations for the coming year. We also report on several important steps in the growth and development of the charity.

Haemochromatosis UK (HUK) is a patient led membership-based charity and patient organisation. HUK has over 1,700 paid-up members and also links thousands of GH patients through events, social media and other activities.

The trustees consider the Charity Commission's guidance on public benefit when planning and reviewing spending, activities and budgets. The trustees are all people who have GH themselves, which ensures that we do not lose sight of our priorities. The trustees are aware of the risk of strategic drift and proposed activities are judged against a four-year strategic plan; the current strategic planning period covers 2017-2020.

The charity increased income in 2018 to a total of £344,486 (2017: £139,207). A substantial and unexpected surplus was recorded, due

predominantly to a significant increase in personal giving and the launch and great success of The Iron Games. A report on the games, our plans for spending the funds generated, full accounts, and our treasurer's report all follow later in this document.

### An important thank you message

As ever, the trustees would like to extend grateful thanks to volunteers, members, donors, fundraisers, activists, advisers and other supporters for their contribution over the year.

We make no apologies for this being a near-repetition of a paragraph in last year's report, we simply could not continue without you.

There are too many individuals to mention here. Many have undertaken challenges, organised events, made substantial donations, volunteered to help run group meetings ... the list goes on. Every charity relies on such support and it is difficult in a few words to convey the importance of what you do for us and for people affected by haemochromatosis; we thank you all sincerely.

### Trust and company donations

This year, thanks in part to the contracting of a part time fundraiser, we have enjoyed substantially increased support from charitable trusts. We have also received support from corporate bodies. The Trustees would like to extend their grateful thanks and public acknowledgment to all such supporters.

#### *Corporate donations*

Toureen Group were our largest supporter financially. The company also sponsored and organised The Iron Games and have been staunch partners throughout the year.

**Toureen Group** 

We also acknowledge the very generous support of the many construction firms that took part in

The Iron Games 2018, the success of which has turned our aspiration to run a three-year GH education programme into a reality. In no particular order, donors who participated alongside Toureen were:

Careys PLC	Danny Sullivan Group
Oliver Connell	Ground Construction Ltd
Mitchellson	ECL Civil Engineering
PJ Keary	Addington Formworks
GetJar Ltd	Owen Fabrications Ltd
Pod Trak	J Reddington Ltd Group
P Colohan & Co	J Murphy & Sons
ASM Recycling	

The Iron Games were also sponsored by:

Cara Stationery  
TMD Insurance Group  
McGee Group Ltd

During the year we also received financial support from the following companies:

Perspectum Diagnostics  
Moore Blatch Solicitors



#### *Charitable Trusts*

In 2018 we increased our activity appealing to charitable trusts for grants to support specific elements of our work.



Special mention and thanks must go to the trustees of The Shears Foundation who have taken a specific interest in our education work and events. Their kind donation of £20,000 seeded the GH Education Programme and gave us the basis and confidence to commit and raise other funds that will allow us to deliver it.

We also received financial support from the

following trusts. Some of these grants are to support work being delivered in 2019 and this is reflected in our accounting.

The Souter Charitable Trust  
Lord Leverhulme Charitable Trust  
The Sylvia Adams Trust  
The Barbour Foundation  
The Rothley Foundation  
The Schroder Charitable Trust



We are grateful to The National Lottery for funding many of the costs of our participation in World Haemochromatosis Week in June.

#### *Trustees' review of the year*

##### *Highlights*

In terms of fundraising, the year was dominated by The Iron Games, discussed later in this report.

In terms of our project activity, 2018 was dominated by the analysis of the 2017 GH Patient Survey, and the presentation of the results and calls to action at The House of Commons in October. This project has proved to be a turning point for the charity as an influence for change.

##### *Information & Support*

Haemochromatosis UK continued to deliver high quality information and support to patients and others with an interest in GH. Our events programme included The GH Patients' Conference in Paddington (London) and three Patient Information Days delivered in Liverpool, Edinburgh and Bristol. These events brought together a total of nearly 300 patients to interact with speakers, other experts and each other. Feedback from the events has been extremely

positive and our intention is to deliver a similar programme in 2019.

We were very proud of the 2018 GH Patients' Conference, which brought together 120 patients and numerous experts to an outstanding event in London. The professionalism of our event delivery team is to be commended, and the feedback from delegates was, once again, that the conference is a crucial information event.

Haemochromatosis UK also continued to expand the level of engagement online through our website and social media. This is a powerful tool, and we plan to carefully extend this further in 2019, for example through the launch of an Instagram presence and the use of microsites for specific projects and fundraising activities.



In 2018 the number of 'hits' to our main website increased by a third to over 5.1m and the number of people using our social media channels increased by 40% to nearly 10,000.

These figures reflect the importance of the platforms and the associated technology, and the substantial increases reflect our continuing and concerted efforts to engage directly with patients and provide high quality, credible information in a world threatened by online misinformation.

We started a review of our information material that will include a rewriting of *The Haemochromatosis Handbook*. We recognise that this publication is a 'bible' for many of our members and other patients and it is essential that it is updated to reflect current knowledge and the results of the 2017 patient survey.

The Haemochromatosis Helpline responded to about 800 calls and emails during the year, and our volunteer helpliners report increases in the number, length and complexity of calls. As UK-

wide awareness of GH and our support services improves, we will continue to invest in training and equipment for this service, assuming we can secure the funding. In 2018 two training weekends brought the helpline team together for important updates and learning sessions.

### Education

A number of education projects were progressed in 2018 and this activity will continue in 2019 and beyond. It is an essential complement to our support work for patients. Primarily our education work is aimed at healthcare professionals in order to improve knowledge and care standards.

The development of an e-learning module on iron overload for GPs was progressed in 2018 and this will be launched in early 2019. This will give us a tool to reach some 57,000 GPs who are members of The Royal College of General Practitioners (RCGP). RCGP will work with us to encourage completion of the training which will be CPD accredited.

Our Venesection Nurses Study Day in April 2018 was accredited for CPD by The Royal College of Nursing and brought together over 100 nurses from across the UK (and indeed beyond). From the feedback received and responses to us running a second event we know this was very successful.




A new project to develop accredited national best practice protocols for the venesection process emerged from the study day. Authors were engaged and as we head into 2019 we intend to submit draft papers for critique by nurses attending our second study day in April.

Plans for the Genetic Haemochromatosis Education Programme (GHEP) were finalised once funding was confirmed and, at the time of

producing this report, we are in the process of recruiting a full time Education Manager to deliver the project to healthcare professionals across the UK. This is a major investment – GHEP will be the largest venture ever by Haemochromatosis UK and will run over 3 years with a budget of approximately £1/3m. GHEP is the culmination of ideas, discussions and planning stemming back to 2016 and we are delighted that 2018 has seen it become a reality, something we regard as a major achievement.

### Awareness

In 2018 we recruited into a new post of Communications Officer, reflecting our commitment to raising awareness as a core activity.



Tamana Gulati's role includes mainstream media work, engaging with professional bodies and publications, and further developing our online and social media presences.



Working with our counterparts from other countries, we were instrumental in the relaunch of World Haemochromatosis Week (WHW) in 2018. WHW is now co-ordinated across at least 15 countries and we took an active part, launching the campaign at an event in Liverpool attended by the city's Lord Mayor. During the week we distributed hundreds of information packs and T-shirts, thousands of stickers, tattoos and leaflets, and secured tens of thousands of video views online. Most of this work was funded by The National Lottery and in 2019 we plan similar activity (subject to funding of course).

During the year we secured articles in several professional publications, notably in October and November following the publication of our report *Living With the Impact of Iron Overload*.

Awareness is a difficult thing to measure but levels of online and media activity are as good an indicator as we are likely to have in the short term. By these measures, we are very pleased with what was achieved in 2018.

### Research

In line with our operational plan for 2018, and our broader strategy for the period 2017-2020, trustees did not make any grants for research in 2018, with the exception of two small travel grants for Dr Patrick Kiely and Professor Rob Evans to attend scientific events.

Whilst we are not specifically calling for research proposals we will accept and review applications that address aspects of the condition where we can make a case to external funders for support, or work on collaborative research funding bids.

Following a wider call for proposals, the board approved a payment to The University of Surrey of just under £10,000 for a project to analyse and report on the responses to our 2017 GH Patient Survey. This investment in an in-depth analysis was needed because the survey had a huge response, generating a much more complex dataset than we were able to analyse ourselves.

### *The survey report and resulting calls to action*

At the beginning of 2018, we believed that the 2017 patient survey, with over 2,000 respondents, had generated a huge opportunity to create a meaningful report that could influence the future of GH on the national healthcare agenda. During the year this did indeed prove to be the case.

As noted above The University of Surrey were chosen to complete the analysis. Dr Kimberly Smith and her colleagues produced the report *Living With the Impact of Iron Overload* and this was launched, together with our resulting 'calls to action', at an important and highly successful event at The House of Commons in October.

The report has already been instrumental in stimulating a change in attitude towards GH. We

have been able to demonstrate that GH is not a condition that only specialists should be concerned with, that it is not rare, and that it cannot continue to be ignored. We have engaged with NICE and other bodies as a direct result of the project, which has clearly shown that the chronic nature of the many problems caused by iron overload merit the condition being moved further up the UK's national healthcare agenda.



Our 5 calls to action emanating from the analysis were presented in a further document at the same event, entitled *Strike While the Iron is NOT* underscoring the need for diagnosis and treatment before iron builds up to toxic levels. It is worth us reiterating those calls here:

- The consistent adoption of current clinical guidelines for GH
- Research to improve our understanding of disease mechanisms
- Research to quantify the true impact of chronic aspects of GH, and how that might be ameliorated
- The development of *further* clinical guidelines for GH
- The establishment of an All Party Parliamentary Group (APPG) for genetic haemochromatosis

The full report from The University of Surrey, our commentary, and *Strike While the Iron Is NOT* are available to download from our website.

We were very proud and pleased to engage with dozens of parliamentarians at Westminster when

the report was launched. We were delighted with the response of the many MPs who expressed support for our work and offered to engage with us further, leading directly to the creation of the called-for APPG.

*The All Party Parliamentary Group for Genetic Haemochromatosis*

Trustees are especially pleased that the call to action to create an APPG was taken up by Mark Pawsey, MP for Rugby where the charity is based. We believe that this offers a really exciting opportunity to influence things, further increase our credibility and standing, and engage with the Department of Health and NHS.



The group was agreed right at the end of 2018, and met for the first time and was formalised in January 2019. In the coming year the group will get down to work, but it is our 2017 and 2018 efforts that have led to the APPG so it would be remiss of us not to report this success here.



*Report launch event at the House of Commons On 31 October 2018. Picture shows healthy discussion between patient, politician and professor!*

*(left) The Lord Mayor of The City of Coventry (and haemochromatosis patient) Cllr John Blundell (centre) Mr Mark Pawsey, MP for Rugby, and Chair of the new APPG for Genetic Haemochromatosis (right) Professor Janus Jankowski, Gastroenterologist and adviser to NICE.*

## *Fundraising*

None of the activity described on pages 3 to 7 would be a possible without money, and so like every charity we invest time and resources in the generation of funding.

We do this through bidding for grants for specific activities, encouraging individuals to donate and fundraise for us, and by building relationships with potential corporate donors.

In 2018 we invested in some professional fundraising expertise to develop bids to various funders for some of our projects. For example, a bid to The National Lottery resulted in funding for World Haemochromatosis Week, and our three 2018 Patient Information Days were partially funded by support from charitable trusts. We intend to build on this early success in 2019.

Numerous individuals have raised funds for the charity by taking part in events and organising community events. From golf days to tea parties, marathons to parachute jumps, these donations make a significant contribution.

In 2018 we were extremely fortunate to meet the team from Toureen Group, an Irish construction firm based in London. The founding family is affected by haemochromatosis and the company have been very keen to work with us and support us, especially in respect of our education work intended to improve patient pathways and reduce the average age of diagnosis.



Toureen Group organised, sponsored, and took part in the inaugural *Iron Games*. The games, now sponsored by Toureen for 2019 and 2020 as well, is a series of four sporting competitions between Irish construction firms – hurling, Gaelic football, soccer and golf (pictured). The Iron Games contributed over £110,000 in 2018 and marked a turning point for Haemochromatosis UK, enabling us to both expand our education activities and make plans to strengthen our infrastructure.

## *Organisational development*

At last year's Annual General Meeting our new Chair Corrina Towers said "Haemochromatosis UK is a big small charity that needs to become a small big charity", reflecting the need for us to influence at high level and build the capacity needed to deliver projects such as GHEP.

With this aspiration comes a need to develop and change as an organisation. Resources need to be brought in and then managed, systems need to cope as the organisation grows, we need to formalise how we work with our advisers, and a fresh strategic plan needs to define our future.

In 2018 we took several steps along these lines. As already noted we created and resourced a vital communications function. We also invested in administrative support for the Chief Executive and Treasurer and, at the end of the year, we committed more resources to investment in IT systems, recognising that technology underpins literally everything that we do.

As we head into 2019 the board plans to create and appoint to a second senior management position, so we will have an Operations Executive working for and alongside a Chief Executive. This investment will substantially increase our capacity, enable us to progress key projects, and significantly reduce the risks to the charity associated with having such a heavy reliance on one individual as we have had with David.

The board is growing your charity, but always with an eye on our sustainability. The appointment in 2019 of a second senior staff member is crucial to



our development but not without risk, we will also have to ensure that income is maintained and indeed continues to rise.

The current Strategic Plan covers the period 2017-2020 but next year your board will review this in the light of the significant changes and achievements of the last two years.

In summary, HUK has enjoyed a very successful year, increasing influence and resources, whilst also maintaining and growing our core information and support services. The board is delighted with this and very positive about our future.

## 5. Governance

### Board

The board will always include a majority of people affected by GH or with a family member who is affected. This ensures that the organisation remains focused on its objectives. However, the board is also conscious of the imperative to include the appropriate skills amongst its number.

2018 saw several changes, as three trustees' terms of office ended in April; former Chair Mr Howard Don, Mr Paul Hirons, and Mr Nick Howes all chose not to stand for re-election. We also welcomed two new trustees to the board; Miss Katharine Hough and Mrs Michelle Weerasekera.

In October, the then interim chair Ms Corrina Towers was elected as permanent Chair, a position she will hold until April 2021. The board of eight is felt to be strong going into 2019; however there is scope to recruit further during the year if a candidate offers suitable skills.

*"... I am excited for the next 12 months as we continue to raise awareness, educate healthcare professionals, support patients and their families and encourage research to help people live with iron overload ..."*

*Corrina Towers, Chair, Haemochromatosis UK*

Trustees are responsible in law for the financial and strategic management of the charity. New trustees complete an induction process based on briefings by existing trustees, our Chief Executive and medical advisers, and material provided by The Charity Commission.

Trustees are expected to attend all trustee meetings and the charity's annual conference and AGM, contribute meaningfully to decision making, and act in accordance with good practice guidance issued by the Charity Commission.

Our record with the commission is at [www.charitycommission.gov.uk](http://www.charitycommission.gov.uk) and can be found by searching there using charity number 1001307.

## The Executive

The Trustees delegate responsibility for day-to-day operations to the Chief Executive, who is supported by several members of staff.

The executive team is expected to grow again in 2019 with the appointment of the Education Programme Manager as outlined earlier in this report, and the creation of a second senior management role, that of Operations Executive.

The Operations Executive and Chief Executive will work closely together and form a fledgling Senior Management Team that will be built upon in the future.

As well as contributing in their governance roles, several trustees also support the Chief Executive on a practical level (still on a voluntary basis) through involvement with project work.

## Strategic Planning

2019 will be the third of the current four-year strategic planning period 2017-2020. However, significant changes and advances mean that the strategic plan will be formally reviewed in the latter half of the coming year and a new plan formulated for the period 2020-2024.

The balance of emphasis is likely to move more to education and the role of the newly created APPG will have to be considered and incorporated. Changes will also reflect the fact that the charity is increasingly influential at a higher level than before.

## 6. Finance

### Income

Our total income for the year exceeded budget by a substantial sum, totalling £344,486 compared with £139,207 in 2017.



The increase was brought about partly by the very successful partnership that we developed with The Toureen Group, who arranged and sponsored The Iron Games referred to in earlier sections of this report. This unplanned, additional net revenue of some £110,000 has enabled us to bring forward the implementation of plans that would otherwise only have been considered in years to come.

In addition to the Iron Games income, the charity's increasing profile has brought about a growth in income from membership subscriptions, personal and corporate donations, legacies, and awards from charitable trusts.


### Restricted and designated funds

Total income comprises different types of funds. **Restricted funds** are those that a donor has specified must be used for a specific project or purpose. **Designated funds** are those allocated to specific projects by the trustees on a discretionary basis. **Unrestricted funds** have been received without restriction and are used to achieve the charity's objectives at the trustees' discretion, and have not been allocated to any particular thread of work or project by the donor.

Included in the total income for the year is £44,424 of restricted funds, of which £17,294 was spent during the year. Further detail is contained in the full accounts from page 14 onwards.

### Fundraising Activities

During 2018 we continued our programme of fundraising events such as participation in The



London Marathon and The GH Challenge. Sadly however, places in The London Marathon are now too expensive for us to justify participation in future years, so we will wind down our presence there as the ones we have are filled. Instead, we are placing emphasis on The Great North Run and similar lower cost events from 2019.



We continued to encourage the *Friends Against Iron Overload* (regular giving) scheme, and indeed in May 2019 a new campaign to recruit more regular donors is planned. *Friends Against Iron Overload* is a source of reliable monthly core income and is crucial to our future.

As noted above, we enjoyed some success as a result of investment in professional fundraising services and this will continue.

We were proud to have been chosen as mayoral charity of the year 2018-19 by The Lord Mayor of Coventry Cllr John Blundell.

### *Expenditure*

Total expenditure increased in 2018 to £248,169 from £143,602 in 2017. Ongoing expenditure levels were held in line with budget expectations. The Trustees are satisfied that cost management remains effective and that they are commensurate with the significant advances being made in delivering on the charity's objectives. However, the opportunity presented by the increased level of income allowed us to begin to accelerate plans and activities that were not originally budgeted for, including the appointment of a Communications Officer,

investment in IT, and improvements to our office facilities, as well as press ahead with recruitment of the Education Manager.

In our statutory accounts, overheads (primarily salaries and office costs) are allocated to six headings (raising funds, governance, and our four charitable objectives) based on the time spent on each.

### *Investment policy*

Our investment policy remains unchanged; we will use only secure UK bank deposits on notice or fixed terms of up to one year. We do not plan on investing in equities or other risk-bearing investments.

### *Cash Reserves*

The board has, during the year, reconsidered its policy of maintaining cash reserves equal to six months operating expenditure as it was considered that this policy resulted in excess levels of cash being unavailable for charitable purposes. A more flexible policy has now been established by the board. This will ensure that funds are available to enable the charity to best weather a significant downturn in income, or to meet significant, unexpected expenditure, or to provide sufficient funds to meet obligations in the event of HUK being wound up. The minimum level of cash reserves required will be reviewed annually by the board. At year-end, the charity holds unrestricted cash reserves considered by the board to be in excess of requirements.

### *Conclusion*

We can report that Haemochromatosis UK is in a strong financial position when compared to previous years. A break-even result was planned for the 2018 year. Satisfyingly, we can, however, report an excess of income over expenditure for the year of £96,317.

One of the board's key financial priorities is to ensure the long-term sustainability of the charity. This is fundamental if we are to continue to grow

our influence and increasingly achieve our objectives. To achieve this the board is conscious of the need to improve the relationship between longer term expenditure commitments on the one hand and the stability of our longer-term income sources on the other.

#### Accounts

The directors (trustees) present this report to the members, together with the annual accounts and notes on page 14 onwards, for the year ended 31 December 2018.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies' regime. The profit and loss account has not been delivered to the Registrar of Companies.

Approved by the board.



Ms Corrina Towers  
Chair  
April 2019

Mr Roger Keyte  
Treasurer  
April 2019



**Haemochromatosis UK**  
**Statement of financial activities for the year**  
**01 January 2018 to 31 December 2018**

	Note	Restricted £	Designated £	Unrestricted £	Total £	2017 £
<b>Incoming resources</b>						
Subscriptions	1b	0	0	38,410	<b>38,410</b>	30,577
Donations	1b	44,015	10,000	201,212	<b>255,227</b>	59,140
Gift Aid		0	0	22,343	<b>22,343</b>	14,617
Charitable activities		0	0	17,576	<b>17,576</b>	24,915
Other income		409	0	9,303	<b>9,712</b>	8,638
Interest receivable		0	0	1,218	<b>1,218</b>	1,320
<b>Total incoming resources</b>		<b>44,424</b>	<b>10,000</b>	<b>290,062</b>	<b>344,486</b>	<b>139,207</b>
<b>Expenditure</b>						
Information & Support		(694)	0	(73,888)	<b>(74,582)</b>	(54,988)
Education & Awareness		(16,600)	(11,894)	(64,199)	<b>(92,693)</b>	(35,755)
Research		0	0	(12,159)	<b>(12,159)</b>	(4,653)
International expenses		0	0	(4,613)	<b>(4,613)</b>	(3,331)
<b>Total charitable activities</b>		<b>(17,294)</b>	<b>(11,894)</b>	<b>(154,859)</b>	<b>(184,047)</b>	<b>(98,727)</b>
Cost of generating funds		0	0	(49,661)	<b>(49,661)</b>	(32,648)
Governance		0	0	(14,461)	<b>(14,461)</b>	(12,227)
<b>Total resources expended</b>		<b>(17,294)</b>	<b>(11,894)</b>	<b>(218,981)</b>	<b>(248,169)</b>	<b>(143,602)</b>
Net income/(expenditure)		27,130	(1,894)	71,081	<b>96,317</b>	(4,395)
Taxation	1e	0	0	0	<b>0</b>	0
<b>Total surplus / (deficit)</b>		<b>27,130</b>	<b>(1,894)</b>	<b>71,081</b>	<b>96,317</b>	<b>(4,395)</b>
<b>Reconciliation of funds</b>						
Total funds brought forward		1,162	10,000	120,829	<b>131,991</b>	136,386
<b>Total funds carried forward</b>		<b>28,292</b>	<b>8,106</b>	<b>191,910</b>	<b>228,308</b>	<b>131,991</b>

The statement of financial activities overleaf includes all gains and losses in the year.

All incoming resources and resources expended derive from continuing activities.

**Haemochromatosis UK, Company Number 2541361**  
**Balance Sheet at 31 December 2018**

	Note	2018 £	2017 £
Current assets:			
Debtors	3	4,107	7,148
Cash at bank and in hand		245,188	127,756
		<u>249,295</u>	<u>134,904</u>
Creditors			
Amounts falling due within 1 year	4	(20,987)	(2,913)
Net current assets		228,308	131,991
Net assets		<u>228,308</u>	<u>131,991</u>
Capital and reserves:			
Income/expenditure account		228,308	131,991
Total charity funds		<u>228,308</u>	<u>131,991</u>
Funds:			
Unrestricted funds		191,910	120,829
Designated funds		8,106	10,000
Restricted funds		28,292	1,162
Total charity funds		<u>228,308</u>	<u>131,991</u>

Approved by the board.



Ms Corrina Towers  
 Chair  
 April 2019



Mr Roger Keyte  
 Treasurer  
 April 2019

**Notes to the accounts for the period**  
**01 January 2018 to 31 December 2018**

1. Accounting policies

- The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland.
- Subscriptions, donations and legacies are accounted for as they are received.
- Short-term debtors are measured at transaction price (usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost using the effective interest method, less any impairment losses for bad and doubtful debts.

- (d) Short-term creditors are measured at transaction price (usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost using the effective interest method.
- (e) The company is a registered charity and is not liable to Corporation Tax.

## 2. Employees

The total number of employees at 31 December 2018 was 5 (2017; 4)

## 3. Debtors

	2018	2017
	£	£
Prepayments	4,077	5,843
Other debtors	30	1,305
	<u>4,107</u>	<u>7,148</u>

## 4. Creditors: amounts falling due within one year

	2018	2017
	£	£
Taxes and social security costs	2,431	1,629
Other creditors	18,556	1,284
	<u>20,987</u>	<u>2,913</u>

## 5. Liability of members

The company is limited by guarantee having no share capital and in accordance with the Memorandum and Articles of Association a member is liable to contribute a sum of £1 in the event of the company being wound up whilst (s)he is a member or within one year thereafter.

## 6. Reserves policy

The minimum level of cash reserves required will be reviewed annually by the board. At year end the charity holds unrestricted cash reserves considered by the board to be in excess of requirements.

## **Independent examiner's report to the trustees of Haemochromatosis UK**

We report on the accounts of the company for the period ended 31 December 2018, which are set out on pages 14 to 16 of this document .

### *Respective responsibilities of trustees and examiner*

The charity's trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) or under Regulation 10(1)(a) to (c) of The Charities Accounts (Scotland) Regulations 2006 (the 2006 Accounts Regulations) and that an independent examination is needed. The charity is required by company law to prepare accounts and we are qualified to undertake the examination by being qualified

members of The Institute of Chartered Accountants in England and Wales.

Having satisfied ourselves that the charity is not subject to audit under company law and is eligible for independent examination, it is our responsibility to:

- examine the accounts under section 145 of the 2011 Act and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 (the 2005 Act);
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to our attention.

#### *Basis of independent examiner's report*


Our examination was carried out in accordance with the general Directions given by the Charity Commission and is in accordance with Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended). An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

#### *Independent examiner's statement*

In connection with our examination, no material matters have come to our attention which give us cause to believe that in any material respect:

- accounting records were not kept in accordance with section 130 of the Charities Act 2011 and section 44(1)(a) of the 2005 Act
- the accounts did not accord with the accounting records
- the accounts did not comply with the accounting requirement of the Charities Act 2011, section 44(1)(b) of the 2005 Act and Regulation 8 of the 2006 Accounts Regulations other than any requirements that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination.

We have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Hicks & Company  
Chartered Accountants  
30 Market Place  
Hitchin SG5 1DY

April 2019



Published April 2019  
© Haemochromatosis UK (The Haemochromatosis Society)  
Charity No 1001307  
[www.haemochromatosis.org.uk](http://www.haemochromatosis.org.uk)

**Haemochromatosis • UK** **+Fe**  
Helping people live with iron overload